New dopamine agonists for the treatment of Parkinson's disease;Neue dopaminagonisten fur die therapie des morbus Parkinson

Aktuelle Neurologie

Volumn 25, Issue 5, 1998, Pages 202-209

  Pogarell, O ^a   Oertel, W H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HUMAN; MOTOR ACTIVITY; PARKINSON DISEASE; RECEPTOR AFFINITY; TREATMENT OUTCOME;

EID: 0031824979     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1017691     Document Type: Article

References (66)

1. 1 Ahlskog, J. E., M. D. Muenter, D. M. Maraganore et al.: Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Arch. Neurol. 51 (1994) 1236-1241
2. 2 Ahlskog, J. E., K. F. Wright, M. D. Muenter et al.: Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin. Neuropharmacol. 19 (1996) 202-212
3. 3 Bernocchi, G., G. Gerzeli, E. Scherini et al.: Neuroprotective effect of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine. Acta Neuropathol. 85 (1993) 404-413
4. 4 Blackard, W. G.: Edema - an infrequently recognised complication of bromocriptine and other ergot dopaminergic drugs. Am. J. Med. 94 (1993) 445
5. 5 Bonucelli, U., P. D'Antonio, C. D'Avino et al.: Dihydroergocryptine in the treatment of Parkinson's disease. J. Neural. Transm., Suppl. 45 (1995) 239-245
6. 6 Bowen, W. P., M. C. Coldwell, F. R. Hicks et al.: Ropinirole, a novel dopaminergic agent for the treatment of Parkinson's disease, with selectivity for cloned dopamine D3 receptors (abstract). Br. J. Pharmacol. 110 (1993) 93 P
7. 7 Brooks, D. J., N. Torjanski, D. J. Burn: Ropinirole in the symptomatic treatment of Parkinson's disease. J. Neural. Transm., Suppl. 45 (1996) 231-238
8. 8 Calne, D. B.: Treatment of Parkinson's disease. N. Engl. J. Med. 329 (1993) 1021-1027
9. 9 Carvey, P. M., Z. D. Ling: The case for neuroprotection with dopamine agonists. Clin. Neuropharmacol. 20, Suppl. 1 (1997) S8-S21
10. 10 Dejong, G. J., J. D. Meerwaldt, P. I. M. Schmitz: Factors that influence the occurrence of response variations in Parkinson's disease. Ann. Neurol. 22 (1987) 4-7
11. 11 Deuschl, G. (Hrsg.): Morbus Parkinson. Alpha-Dihydroergocriptin - ein neuer Dopaminagonist. Thieme, Stuttgart - New York (1995)
12. 12 Diamond, S. G., C. H. Markham, M. M. Hoehn et al.: Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann. Neurol. 22 (1987) 8-12
13. 13 Dodel, R. C., M. Singer, R. Köhne-Volland et al.: Krankheitskosten der Parkinson-Erkrankung. Eine retrospektive dreimonatige Analyse der direkten Kosten. Nervenarzt 68 (1997) 978-984
14. 14 Eden, R. J., B. Costall, A. M. Domeney et al.: Preclinical pharmacology of ropinirole a novel dopamine d2 agonist. Pharmacol. Biochem. Behav. 38 (1991) 147-154
15. 15 Fahn, S.: Controversies in the therapy of Parkinson's disease. Adv. Neurol. 69 (1996) 477-486
16. 16 Fahn, S.: Is levodopa toxic? Neurology 47, Suppl. 3 (1996) S184-S195
17. 17 Fears, R., W. P. Bowen, F. Brown et al.: the novel dopaminergic agent ropinirole selectively binds to cloned dopamine D3 receptors (abstract). Can. J. Neurol. Sci. 20, Suppl. 4 (1993) S68
18. 18 Felten, D. L., S. Y. Felten, R. W. Fuller et al.: Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats. Neurobiol. Aging 13 (1992) 339-351
19. 19 Gerfen, C. R.: Dopamine receptor function in the basal ganglia. Clin. Neuropharmacol. 18, Suppl. 1 (1995) S162-S177
20. 20 Gimenez-Roldan, S., E. Tolosa, J. A. Burguera et al.: Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomised study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin. Neuropharmacol. 20 (1997) 67-76
21. 21 Hagan, J. J., D. N. Middlemiss, P. C. Sharpe et al.: Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol. Sci. 18 (1997) 156-163
22. 22 Hubble, J. P., W. C. Koller, N. R. Cutler et al.: Pramipexole in patients with early Parkinson's disease. Clin. Neuropharmacol. 18 (1995) 338-347
23. 23 Hutton, J. T., J. L. Morris, M. A. Brewer: Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 43 (1993) 613-616
24. 24 Inzelberg, R., P. Nisipeanu, J. M. Rabey et al.: Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 47 (1996) 785-788
25. 25 Jiminez-Jiminez, F. J., J. Lopez-Alvarez, M. Sanchez-Chapado et al.: Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin. Neuropharmacol. 18 (1995) 277-279
26. 26 Korczyn, A. D.: A double-blind study comparing ropinirole and bromocriptine in patients with early Parkinson's disease (abstract). Neurology 46, Suppl. 2 (1996) A159
27. 27 Kreider, M. M., S. Knox, D. Gardiner et al.: A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease (abstract). Neurology 46, Suppl. 2 (1996) A475
28. 28 Kreiss, D. S., B. A. Bergstrom, A. M. Gonzales et al.: Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur. J. Pharmacol. 277 (1995) 209-214
29. 29 Lera, G., J. Vaamonde, M. Rodriguez et al.: Cabergoline in Parkinson's disease: long-term follow-up. Neurology 43 (1993) 2587-2590
30. 30 Lesser, R. P., S. Farm, S. R. Snider et al.: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29 (1979) 1253-1260
31. 31 LeWitt, P. A., C. D. Ward, T. A. Larson et al.: Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 33 (1983) 1009-1014
32. 32 Lieberman, A., S. Imke, M. Muenter et al.: Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating response to levodopa/ carbidopa. Neurology 43 (1993) 1981-1984
33. 33 Lieberman, A., A. Ranhosky, D. Korts: Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group-study. Neurology 49 (1997) 162-168
34. 34 Markham, C. H., S. G. Diamond: Evidence to support early levodopa therapy in Parkinson's disease. Neurology 31 (1981) 125-131
35. 35 Markham, C. H., S. G. Diamond: Modification of Parkinson's disease by long-term levodopa treatment. Arch. Neurol. 43 (1986) 405-407
36. 36 Marsden, C. D., J. D. Parkes: Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977) 345-349
37. 37 Marsden, C. D., S. Fahn: Problems in Parkinson's disease and other akinetic-rigid syndromes. In: Marsden, C. D., S. Fahn (eds.): Movement Disorders 3. Butterworth-Heinemann, Oxford (1994) 117-123
38. 38 Martinoni, E., C. Pacchetti, L. Sibilla et al.: Dihydroergocryptine in the treatment of Parkinson's disease: a six months double-blind clinical trial. Clin. Neuropharmacol. 14 (1991) 78-83
39. 39 Mierau, J., W. D. Bechtel: SND 919 inhibits dopamine release in vivo and in vitro. Psychopharmacol. 96 (1988) 338
40. 40 Mierau, J., G. Schingnitz: Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur. J. Pharmacol. 215 (1992) 161-170
41. 41 Mierau, J., F. J. Schneider, H. A. Ensinger et al.: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. J. Pharmacol. 290 (1995) 29-36
42. 42 Molho, E. S., S. A. Factor, W. J. Weiner et al.: The use of pramipexole, a novel dopamine (DA) agonist in advanced Parkinson's disease. J. Neural. Transm. 45 (1995) 225-230
43. 43 Montastruc, J. L., O. Rascol: A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. J. Neurol. Neurosurg. Psychiatry 52 (1989) 773-775
44. 44 Montastruc, J. L., O. Rascol, J. M. Senard et al: A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J. Neurol. Neurosurg. Psychiatry 57 (1994) 1034-1038
45. 45 Oertel, W. H., N. Qumn: Parkinsonism. In: Brandt, T., H. C Diener, L. R. Caplan et al. (eds.): Neurological Disorders: Course and Treatment. Academic Press, San Diego, California (1996) 715-772
46. 46 Olanow, C. W., S. Fahn, M. Muenter et al.: A multicenter double-blind placebo controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov. Disord. 9 (1994) 40-47
47. 47 Parkinson Study Group: Safety and efficacy of pramipexole in early Parkinson's disease. A Randomised dose-ranging study. JAMA 278 (1997) 125-130
48. 48 Pezzoli, G., E. Martignoni, C. Pacchetti et al.: Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study. Mov. Disord. 9 (1994) 431-436
49. Piercey, M. F., W. E. Hoffmann, M. W. Smith et al.: Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur. J. Pharmacol. 312 (1996) 35-44
50. 50 Poewe, W., A. J. Lees, G. M. Stern: Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 36 (1986) 1528-1530
51. 51 Poewe, W.: Pergolid. Akt. Neurol. 22 (1995) 71-74
52. 52 Pogarell, O., G. Künig, W. H. Oertel: A non-ergot dopamine agonist, pramipexole, in the therapy of advanced Parkinson's disease: Improvement of parkinsonian symptoms and treatment-associated complications. A review of three studies. Clin. Neuropharmacol. 20, Suppl. 1 (1997) S28-S35
53. 53 Rascol, O.: A double-blind L-Dopa-controlled study of ropinirole in patients with early Parkinson's disease (abstract). Neurology 46, Suppl. 2 (1996) A160
54. 54 Rascol, O., A. J. Lees, J. M. Senard et al.: Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin. Neuropharmacol. 19 (1996) 234-245
55. 55 Rascol, O., A. J. Lees, J. M. Senard et al.: A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-Dopa-treated parkinsonian patients. Adv. Neurol. 69 (1996) 531-534
56. 56 Rinne, U. K., F. Bracco, C. Chouza et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind, L-dopa-controlled trial (abstract). Mov. Disord. 12, Suppl. 1 (1997) 64
57. 57 Robertson, G. S., C. S. Tham, C. Wilson et al.: In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J. Pharmacol. Exp. Ther. 264 (1993) 1344-1351
58. 58 Ropinirole 043 Study Group: A double-blind comparative study of ropinirole vs. bromocriptine in the treatment of parkinsonian patients not optimally controlled on L-Dopa. Mov. Disord. 11, Suppl. 1 (1996) 188:P705
59. 59 Shannon, K. M.: New Alternatives of the management of early Parkinson's disease (PD): Pramipexole monotherapy in mild to moderate PD. A review of three studies. Clin. Neuropharmacol. 20, Suppl. 1 (1997) S22-S27
60. 60 Shannon, K. M.: Pramipexole monotherapy in early Parkinson's disease: long-term follow-up and interim analysis. XIIth International Symposium on Parkinson's disease, London, March 23-26 (1997)
61. 61 Strange, P. G.: Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov. Disord. 8 (1993) 263-270
62. 62 Villa, R. F., R. Arnaboldi, B. Ghigini et al.: Parkinson-like disease by 1-methyl-4-phenyl-1,2,3.6-tetrahydropyridine (MPTP) toxicity in Macaca Fascicularis: synaptosomal metabolism and action of dihydroergocriptine. Neurochem. Res. 19 (1994) 229-236
63. 63 Wheadon, D., K. Wilson-Lynch, D. Gardiner et al.: The efficacy and safety of ropinirole in early parkinsonian patients not receiving dopaminergic therapy: a multicenter double-blind study (abstract). Neurology 46, Suppl. 2 (1996) A159
64. 64 Willner, P., S. Lappas, S. Cheeta et al.: Reversal of stress-induced anhedonia by the dopamine receptor agonist pramipexole. Psychopharmacology 115 (1994) 454-462
65. 65 Wright, C. E., L Sisson, A. K. Ichhpurani et al.: Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J. Clin. Pharmacol. 37 (1997) 520-525
66. 66 Yahr, M. D.: Long-term levodopa in Parkinson's disease. Lancet 1 (1977) 706-707